Concise Prescribing Info
Management of moderate to severe pain.
Dosage/Direction for Use
Initially 5 mg for 7 days. Apply patch to a non-irritated, intact skin on upper outer arm, upper chest, upper back or side of the chest. Continue every 3-7 days until adequate analgesia is achieved. Dose should not be increased at <3 day intervals.
Special Precautions
Patients w/ severely impaired resp function or are concurrently receiving MAOIs & those who have received w/in the previous 2 wk. Head injury, intracranial lesions or increased intracranial pressure, shock, reduced level of consciousness of uncertain origin, severe hepatic impairment. May lower seizure threshold in patients w/ history of seizure disorder. Severe febrile illness. Patients w/ known or suspected problems w/ drug or alcohol abuse or serious mental illness. Analgesia in the immediate post-op period or in other situations characterized by rapidly varying analgesic requirement. May precipitate an abstinence syndrome depending on the level of physical dependence, timing & dose of buprenorphine in patients who are physically dependent on full μ-opioid agonists. May impair the ability to drive or operate machinery. Pregnancy & lactation. Childn <18 yr.
Adverse Reactions
Dizziness, headache, somnolence; constipation, nausea, vomiting; pruritus; application site reaction (erythema, edema, pruritus, rash). Anorexia; confusion, depression, insomnia, nervousness, anxiety; tremor; dyspnea; abdominal pain, diarrhea, dyspepsia, dry mouth; rash, sweating; asthenic conditions (including muscle weakness), peripheral edema.
Drug Interactions
MAOIs or who have received MAOIs w/in the previous 2 wk. Concomitant use w/ CNS depressants including sedatives or hypnotics, general anesth, other opioid analgesics, phenothiazine, centrally acting antiemetics, benzodiazepines & alcohol may cause resp depression, hypotension & profound sedation or potentially result in coma. May decrease rate of hepatic elimination w/ general anesth (eg, halothane). Elevated plasma conc w/ CYP3A4 inhibitors. Increased clearance w/ enzyme inducers (eg, phenobarb, carbamazepine, phenytoin & rifampin).
ATC Classification
N02AE01 - buprenorphine ; Belongs to the class of oripavine derivative opioids. Used to relieve pain.
Norspan transdermal patch 5 mg
2 × 1's (P2,270.27/pack)
Norspan transdermal patch 10 mg
2 × 1's (P3,405.4/pack)
Norspan transdermal patch 20 mg
2 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in